USP <800> Cleanroom Requirements For Hazardous Drugs

What containment actually requires: negative pressure, external venting, and the rooms that have to hold both.

USP General Chapter <800> sets the standards for handling hazardous drugs in healthcare settings. Where USP <797> protects the preparation from the room, USP <800> protects the people and the environment from the preparation. Those two goals pull a facility in opposite directions, which is why a hazardous drug cleanroom is harder to design than a conventional one.

This page states what USP <800> requires of a facility: how hazardous drugs are identified, what a containment cleanroom has to hold, how hazardous drugs must be stored, and where USP <800> and USP <797> have to be reconciled.

What counts as a hazardous drug

USP <800> does not maintain its own drug list. It points to the NIOSH List of Hazardous Drugs in Healthcare Settings, published by the National Institute for Occupational Safety and Health. The current edition is the 2024 list, published in the Federal Register on December 20, 2024 as CDC publication number 2025-103.

The 2024 list is organized into two tables. Table 1 covers antineoplastic drugs, which carry the strictest handling expectations. Table 2 covers non-antineoplastic drugs that still meet one or more of the NIOSH hazard criteria. A facility must maintain its own list of the hazardous drugs it handles, reviewed at least every 12 months and whenever a new agent is introduced.

If your hazardous drug list has not been reviewed since the 2024 NIOSH update, that is the first thing to check. The list changed, and a facility list built on the previous edition is out of date.

The Assessment of Risk

Full containment is not required for every hazardous drug in every form. USP <800> permits a facility to perform an Assessment of Risk for certain dosage forms and apply alternative containment strategies instead.

The Assessment of Risk is a documented evaluation. For each hazardous drug and dosage form it considers the type of drug, the dosage form, the risk of exposure, the packaging, and how the drug is manipulated. Where the assessment supports it, the facility can adopt alternative containment strategies and work practices rather than the default engineering controls.

Two limits are worth knowing. Antineoplastic drugs requiring manipulation beyond counting or repackaging of final dosage forms cannot be exempted, and neither can any active pharmaceutical ingredient. For everything else, the Assessment of Risk is the mechanism that keeps a facility from over-building. It must be reviewed at least every 12 months and documented.

The vocabulary

USP <800> uses containment-specific terms. They appear on every drawing and in every certification report, so they are worth getting right.

Containment requirements at a glance

The Requirements below define the environmental and engineering controls each room must meet for safe hazardous drug handling.

The ante-room serving a hazardous drug buffer room is positive to adjacent space and ISO 7, not ISO 8. The buffer room itself is negative. A C-PEC that supplies the room’s negative pressure, or that is used for sterile compounding, must run continuously.

Storing hazardous drugs

Storage is the requirement facilities miss most often, because it is easy to think of containment as something that only applies where compounding happens.

Antineoplastic drugs requiring manipulation, and all hazardous drug active pharmaceutical ingredients, must be stored separately from non-hazardous inventory in a room that is externally vented, negative pressure, and provides at least 12 air changes per hour. Refrigerated antineoplastic drugs need a dedicated refrigerator in a negative pressure area, and if that refrigerator sits in a positive pressure space, an exhausted enclosure is required.

Non-antineoplastic, reproductive-risk-only, and final dosage forms of antineoplastic drugs may be stored with other inventory, if the facility’s Assessment of Risk supports it.

Where USP <797> and USP <800> conflict

This is the design problem at the center of every hazardous sterile compounding project, and it is worth being direct about it.

USP <797> wants the buffer room positive, so clean air moves outward and contamination cannot drift in toward the preparation. USP <800> wants the buffer room negative, so hazardous aerosols move inward and cannot escape toward staff. Both requirements apply to the same room when you compound sterile hazardous preparations.

The resolution is the ante-room. The buffer room runs negative at -0.01 to -0.03 in. w.c. and is externally vented, satisfying USP <800>. The ante-room in front of it is held positive at more than 0.02 in. w.c. and classified to ISO 7 rather than ISO 8, so the air entering the buffer room is already clean enough to protect the preparation. Cleanliness is delivered by the ante-room and by HEPA supply at the buffer room ceiling; containment is delivered by the pressure gradient and the exhaust.

Two consequences follow, and both are easier to design for than to retrofit. First, hazardous and non-hazardous sterile compounding cannot share a buffer room, because one has to be positive and the other negative for containment and segregation. A facility doing both needs two buffer rooms. Second, a negative pressure buffer room that is externally vented cannot recirculate, so the air handling load is materially higher than a conventional cleanroom of the same size. That shows up in both the mechanical design and the operating cost.

• The positive pressure requirements on the USP <797> side are on our USP <797> page

Cleaning is four steps, not two

A conventional cleanroom is cleaned and disinfected. A hazardous drug room requires four distinct steps, in order, and each does something the others do not.

• Deactivation. Renders the hazardous drug inert or less hazardous. This step does not exist outside hazardous drug handling, and skipping it means the next steps simply move active drug around.
• Decontamination. Removes hazardous drug residue from the surface.
• Cleaning. Removes organic and inorganic soil with a germicidal detergent.
• Disinfection. Destroys microorganisms. Required for sterile compounding areas.

Agents must be chosen against the drugs actually handled, and surfaces have to tolerate all four. This is a common point of failure in rooms specified without hazardous drug handling in mind, and it usually shows up as degraded finishes within the first two years.

Beyond the facility

USP <800> covers more than the room. Personal protective equipment, spill control, and medical surveillance are all part of the chapter, and a compliant operation needs all of them.

• Personal protective equipment. Chemotherapy-rated gloves and gowns, and eye, face, and respiratory protection where the activity warrants it.
• Spill control. Spill kits available wherever hazardous drugs are handled, with trained staff and written procedures.
• Medical surveillance. A program for personnel who routinely handle hazardous drugs.

These are operational programs rather than facility design, so they sit outside what we build. We mention them because a facility assessment that ignores them is incomplete, and because the room has to physically support them: somewhere to don and doff, somewhere to store a spill kit, somewhere to stage waste.

Is USP <800> enforceable?

Yes. A good deal of published material still describes USP <800> as informational, which was true during the period when the chapter was under appeal. That period ended. USP <800> became compendially applicable on November 1, 2023, alongside the revised USP <795> and USP <797>.

Enforcement in practice comes from state boards of pharmacy, accrediting bodies, and in some states occupational health and safety regulators. Adoption varies by state, and a few states have their own hazardous drug rules that go further than USP <800>. Check your own state board before finalizing a design, because the state requirement governs where it is stricter.